[A combination of solifenacin succinate and naftopidil in the treatment of female overactive bladder].
Lizhi Huo, Han-guo Jing, Teng-chun Wang, Shou-xian Yuan, Xiu-hua Luan, Ke-cun Guo, Benkang Shi
Abstract
Lizhi Huo, Han-guo Jing, Teng-chun Wang, Shou-xian Yuan, Xiu-hua Luan, Ke-cun Guo, Benkang Shi
Abstract
OBJECTIVE: To explore the effective therapy of female overactive bladder unresponsive to behavior training. METHODS: A total of 67 patients with female overactive bladder unresponsive to behavior training were enrolled from January 2012 to January 2013 at Liaocheng Second People's Hospital. They were randomized into trial and control groups (Iand II). Their mean age was 39.8 (19-57) years. And the mean disease course was 3.8 (1-16) years. The trial group (n = 24) received oral formulations of solifenacin succinate (5 mg, once a day)and naftopidil (25 mg, every evening). The control group I (n = 22) had only solifenacin succinate and the control group II (n = 21) only naftopidil. The treatment lasted for 4 weeks. The time of urination per day, average amount of mona-urination and maximum amount of mona-urination were observed. The changes of all parameters before and after treatment were assessed. And statistic analysis was performed. RESULTS: The urinary urgency score of the trial, control group I and control II groups were 0.8 ± 0.1, 1.8 ± 0.8, 2.1 ± 0.9; and the times of urination per day 9 ± 4, 13 ± 4, 14 ± 5, average amount of mona-urination (295 ± 79), (211 ± 67), (185 ± 64) ml and maximum amount of mona-urination (352 ± 88), (292 ± 75), (235 ± 69) ml respectively. These parameters showed significant differences between the trial and control groups (all P < 0.05). CONCLUSION: A combination of solifenacin succinate and naftopidil can effectively relieve the symptoms of female overactive bladder and improve the life quality.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE: To explore the effective therapy of female overactive bladder unresponsive to behavior training. METHODS: A total of 67 patients with female overactive bladder unresponsive to behavior training were enrolled from January 2012 to January 2013 at Liaocheng Second People's Hospital. They were randomized into trial and control groups (Iand II). Their mean age was 39.8 (19-57) years. And the mean disease course was 3.8 (1-16) years. The trial group (n = 24) received oral formulations of solifenacin succinate (5 mg, once a day)and naftopidil (25 mg, every evening). The control group I (n = 22) had only solifenacin succinate and the control group II (n = 21) only naftopidil. The treatment lasted for 4 weeks. The time of urination per day, average amount of mona-urination and maximum amount of mona-urination were observed. The changes of all parameters before and after treatment were assessed. And statistic analysis was performed. RESULTS: The urinary urgency score of the trial, control group I and control II groups were 0.8 ± 0.1, 1.8 ± 0.8, 2.1 ± 0.9; and the times of urination per day 9 ± 4, 13 ± 4, 14 ± 5, average amount of mona-urination (295 ± 79), (211 ± 67), (185 ± 64) ml and maximum amount of mona-urination (352 ± 88), (292 ± 75), (235 ± 69) ml respectively. These parameters showed significant differences between the trial and control groups (all P < 0.05). CONCLUSION: A combination of solifenacin succinate and naftopidil can effectively relieve the symptoms of female overactive bladder and improve the life quality.
Key concepts: Solifenacin, Urination, Overactive bladder, Medicine, Urology, Randomized controlled trial, Urinary system, Internal medicine